Skip to main content
main-content

20-05-2019 | Chronic obstructive pulmonary disease | Video

ATS 2019: No reduction in COPD exacerbation rate with benralizumab treatment

Gerard Criner reports findings from the placebo-controlled GALATHEA and TERRANOVA trials, demonstrating that add-on benralizumab does not reduce exacerbation rates among patients with moderate to very severe chronic obstructive pulmonary disease (3:27).

Funding for this video was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits